問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

葉昭廷Yeh, Chau-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • chauting@cgmh.org.tw

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉昭廷

List

40Cases

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
8Sites

Terminated8Sites

2018-07-01 - 2020-12-31

Phase II

Randomized, controlled, open label, clinical trial for - adagloxad simolenin/OBI-821 in combination with TACE therapy in hepatocellular carcinoma patients with GALNT14-rs9679162-non-TT genotype

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Adagloxad simolenin (OBI-822)/OBI-821

Participate Sites
5Sites

Terminated4Sites

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2020-10-01 - 2023-06-05

Phase II

A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    ABI-H2158

Participate Sites
5Sites

Not yet recruiting5Sites

2015-09-10 - 2023-12-31

Phase II

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    MEDI4736 / Tremelimumab

Participate Sites
3Sites

Recruiting3Sites

2013-09-01 - 2017-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-09-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Suspended3Sites

2012-06-01 - 2014-08-31

Phase I/II

A Phase I/II, Open-label, Randomized, Active Control, Dose Finding Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 in Interferon-Naïve Subjects with Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Hepatitis B virus

  • Test Drug

    P1101

Participate Sites
9Sites

Terminated9Sites

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2015-03-01 - 2016-10-26

Phase II

A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

  • Condition/Disease

    Hepatitis C

  • Test Drug

    TG-2349

Participate Sites
9Sites

Terminated9Sites

鄭斌男
National Taiwan University Hospital

Division of General Internal Medicine

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB